Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.52 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.42 |
| ▸ | NAAA | Q02083 | 1/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.41 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.41 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 2/20 | 0.40 |
| ▸ | FDPS | P14324 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7505385 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL11063113 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL11065218 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL11068420 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL11001712 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL21046041 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL8216269 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL7516322 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL7516454 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTATML3MBTL1 | |
| SCHEMBL7106837 | 1.00 | MEN1 (0.59) | MEN1KMT2AMAPTATML3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4015511-A1 | OXIDATION CATALYSTS BASED ON MACROCYCLIC COMPOUNDS | CARNEGIE MELLON UNIVERSITY (US) | 2022-06-22 | — | — | EP | disclosed |
| EP-3353157-B1 | OXIDATION CATALYSTS BASED ON MACROCYCLIC COMPOUNDS | UNIV CARNEGIE MELLON (US) | 2021-11-24 | — | — | EP | disclosed |
| EP-2521711-B1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES PHARMA IRELAND LTD (IE) | 2017-08-16 | — | — | EP | disclosed |
| US-9670200-B2 | Quaternary ammonium salt prodrugs | ALKERMES PHARMA IRELAND LIMITED (IE) | 2017-06-06 | — | — | US | disclosed |
| EP-2521711-A1 | QUATERNARY AMMONIUM SALT PRODRUGS | Alkermes, Inc. (US) | 2012-11-14 | — | — | EP | disclosed |
| EP-1465962-B1 | ELECTROCHROMIC POLYMERS AND POLYMER ELECTROCHROMIC DEVICES | UNIV FLORIDA (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | ALKERMES, INC. (US) | 2011-07-21 | — | — | US | disclosed |
| WO-2011084849-A1 | DIARYLDIAZEPINE PRODRUGS FOR THE TREATMENT OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084846-A1 | QUATERNARY AMMONIUM SALT PRODRUGS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| WO-2011084851-A1 | ASENAPINE PRODURUGS | ALKERMES, INC. (US) | 2011-07-14 | — | — | WO | disclosed |
| US-20110166194-A1 | Asenapine Prodrugs | ALKERMES, INC. (US) | 2011-07-07 | — | — | US | disclosed |
| CN-100540627-C | Electrochromic polymers and polymer electrochromic devices | UNIV FLORIDA (US) | 2009-09-16 | — | — | CN | disclosed |
| CN-1615352-A | Electrochromic polymers and polymer electrochromic devices | UNIV FLORIDA (US) | 2005-05-11 | — | — | CN | disclosed |
| EP-1465962-A1 | ELECTROCHROMIC POLYMERS AND POLYMER ELECTROCHROMIC DEVICES | UNIVERSITY OF FLORIDA (US) | 2004-10-13 | — | — | EP | disclosed |
| US-6791738-B2 | CONTROLLING COLOR, BRIGHTNESS AND ENVIRONMENTAL STABILITY; POLY- 3,4-ALKYLENEDIOXYHETEROCYCLES | UNIVERSITY OF FLORIDA | 2004-09-14 | — | — | US | disclosed |
| CN-1121906-C | Long-lived homogenous oxidation catalyst | UNIV CARNEGIE MELLON (US) | 2003-09-24 | — | — | CN | disclosed |
| US-20030174377-A1 | Electrochromic polymers and polymer electrochromic devices | UNIVERSITY OF FLORIDA | 2003-09-18 | — | — | US | disclosed |
| WO-2003046106-A1 | ELECTROCHROMIC POLYMERS AND POLYMER ELECTROCHROMIC DEVICES | UNIVERSITY OF FLORIDA (US) | 2003-06-05 | — | — | WO | disclosed |
| EP-0914206-B1 | LONG-LIVED HOMOGENOUS OXIDATION CATALYSTS | UNIV CARNEGIE MELLON (US) | 2002-12-11 | — | — | EP | disclosed |
| CN-1230903-A | Long-lived homogenous oxidation catalyst | UNIV CARNEGIE MELLON (US) | 1999-10-06 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178068-A1 | Quaternary Ammonium Salt Prodrugs | SLC1A5, IDH1, ASS1 | MEN1 1924/4885KMT2A 872/4885MAPT 3288/4885 |
| US-20110166194-A1 | Asenapine Prodrugs | GRIN1, SCN1B, GRIN2B | MEN1 2381/4885KMT2A 1802/4885MAPT 1129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.